Automating Aimovig Carelon Prior Authorizations: A Workflow Deep Dive
Navigating prior authorization for Aimovig with Carelon requires precise workflow automation to overcome common formulary challenges and ensure timely patient access.
For revenue cycle directors and prior authorization teams, managing specialty drug PAs can be a significant bottleneck. The specific requirements from Carelon, Elevance Health's utilization management subsidiary, for medications like Aimovig (erenumab) necessitate an efficient, integrated approach to minimize denials and accelerate approvals.
Understanding Carelon's Role in Aimovig PA
Carelon, formerly AIM Specialty Health and a key utilization management entity for Elevance Health, plays a critical role in approving specialty medications. For CGRP receptor antagonists like Aimovig, Carelon evaluates clinical necessity against established criteria, often requiring a detailed history of prior treatments and patient-specific conditions before approval.
Aimovig PA Workflow: Pharmacy vs. Medical Benefit
Aimovig (erenumab) is typically covered under the pharmacy benefit, meaning prior authorizations are processed as electronic prior authorizations (ePA) via the NCPDP SCRIPT standard. This distinguishes it from medical benefit drugs that utilize X12 278 transactions. Successful ePA for Aimovig often involves direct communication with specialty pharmacies and meticulous data submission through payer portals or integrated platforms.
Common Formulary and Step-Therapy Hurdles
Aimovig frequently encounters step-therapy requirements imposed by Carelon. Patients are typically expected to have failed trials of multiple first-line, lower-cost preventive migraine therapies, such as beta-blockers, tricyclic antidepressants, or anticonvulsants, before CGRP antagonists are approved. Documentation of these prior treatment failures, including dosages and duration, is paramount for a successful submission.
Essential Documentation for Aimovig Carelon Submissions
Accurate and comprehensive documentation is non-negotiable for Aimovig prior authorizations through Carelon. This includes detailed clinical notes outlining diagnosis (ICD-10 codes for chronic or episodic migraine), patient history, past medication trials and failures, contraindications to alternative therapies, and a clear rationale for Aimovig's medical necessity. Any missing or incomplete information can lead to immediate denials and delays.
Optimizing the Aimovig Carelon ePA Process with Klivira
Klivira's platform automates the complex ePA workflow for Aimovig with Carelon, integrating directly with EMRs to extract relevant clinical data and populate submission forms. Our system facilitates NCPDP SCRIPT submissions, tracks real-time status updates, and streamlines the appeals process, reducing administrative burden and accelerating patient access to critical therapies. This integration ensures adherence to Da Vinci PAS implementation guides where applicable, fostering interoperability.
Frequently asked questions
What is Carelon's specific role in Aimovig prior authorizations?
Carelon, as Elevance Health's utilization management subsidiary, reviews Aimovig prior authorization requests to determine medical necessity based on their clinical criteria. They assess patient history, diagnosis, and prior treatment failures against established guidelines before approving the medication.
Is Aimovig typically covered under pharmacy or medical benefit for Carelon plans?
Aimovig (erenumab) is predominantly covered under the pharmacy benefit for Carelon plans. This means that prior authorization requests are processed as electronic prior authorizations (ePA) using the NCPDP SCRIPT standard, rather than through medical claims processes.
What are common step-therapy requirements for Aimovig with Carelon?
Carelon often requires patients to have attempted and failed trials of several generic, first-line migraine preventive medications, such as beta-blockers, tricyclic antidepressants, or anticonvulsants, before approving Aimovig. Documentation of these prior treatment failures is crucial for approval.
What documentation is critical for a successful Aimovig PA submission to Carelon?
Key documentation includes detailed clinical notes with the specific migraine diagnosis (ICD-10), a comprehensive list of previously failed preventive therapies (including dosages and duration), any contraindications to alternative treatments, and a clear justification for Aimovig's medical necessity.
How does Klivira integrate with Carelon for Aimovig ePA?
Klivira integrates with Carelon's ePA submission portals and leverages the NCPDP SCRIPT standard to automate the submission of Aimovig prior authorizations. Our platform extracts necessary data from your EMR, populates the PA forms, and provides real-time status tracking, streamlining the entire workflow.
Related coverage
Ready to automate this workflow?
See how Klivira automates prior authorizations for your team.
Request a demo